Clinical studies of new therapies intended to treat rare form of blood cancer, has ended in tragedy. Instead of to suppress the development of the disease, the therapy caused the disease progression and deterioration of patients.
We are talking about three patients with T-cell leukemia-lymphoma in adults – a rare type of non-Hodgkin’s lymphoma. It is assumed that this form of cancer is caused by human T-cell lymphotropic virus type 1. The disease progresses rapidly, affecting the lymph nodes, blood cells and other organs. This virus is most common in Japan and countries the Caribbean and some parts of Central and South America, and Africa. Despite the fact that its speakers are millions of people in only 5% of them develop cancer.
There is no consensus about what should be a therapy suitable for patients with T-cell leukemia-lymphoma, adult. Because patients with this diagnosis are invited to participate in clinical trials.
So it was this time examined the efficacy of the drug nivolumab, which is already used to treat other forms of cancer. It was assumed that the experiment will be attended by 20 people, but after the third one received a single dose of the drug showed a sharp progression of the disease, testing was discontinued.
Janakiram Murali (Murali Janakiram), one of the authors of the study, explains that this probably means nivolumab cannot be applied to treat this form of cancer, and in addition should be careful to appoint it to patients with other types of lymphomas.